Prognostication and Management of Decompensated Chronic Liver Disease

Prognostic Assessment

• The European Association for the Study of the Liver recommends using the Child-Pugh score for initial stratification of cirrhosis severity, with scores of 7-10 indicating decompensated disease 1
• The American Association for the Study of Liver Diseases suggests that MELD and MELD-Na scores are essential for transplant prioritization but may underestimate mortality in patients with extrahepatic organ failures 2
• The European Association for the Study of the Liver proposes that the CLIF-C ACLF score provides better prognostic accuracy than MELD for patients with acute-on-chronic liver failure 2
• The North American Society for the Study of Liver Diseases recommends using the NACSELD ACLF score to incorporate advanced extrahepatic organ failure, age, MELD, WBC count, and serum albumin for mortality prediction 2

Management Strategy

• The American Association for the Study of Liver Diseases recommends complete cessation of alcohol consumption in alcoholic cirrhosis to lead to "re-compensation" and improved outcomes in some patients 1
• The European Association for the Study of the Liver suggests that antiviral therapy for HBV-related cirrhosis improves outcomes in selected patients 1
• The American Association for the Study of Liver Diseases recommends direct-acting antivirals for HCV-related decompensated cirrhosis to improve liver function and portal hypertension 1
• The European Association for the Study of the Liver proposes that prevention of cirrhosis progression should be prioritized over simply treating complications as they occur 1

Preventing Disease Progression

• The American Association for the Study of Liver Diseases recommends using enoxaparin to delay hepatic decompensation and improve survival in patients with Child-Pugh scores 7-10 by preventing portal vein thrombosis and reducing intestinal barrier damage 1
• The European Association for the Study of the Liver suggests that pentoxifylline can reduce liver-related complications (infections, renal failure, encephalopathy) by preventing intestinal bacterial translocation 1
• The American Association for the Study of Liver Diseases recommends using propranolol to reduce portal hypertension and decrease risk of various complications (variceal bleeding, ascites, hepatorenal syndrome, spontaneous bacterial peritonitis, encephalopathy) in responders 1

Managing Specific Complications

• The American Association for the Study of Liver Diseases recommends early identification and management of renal dysfunction to improve survival 3
• The European Association for the Study of the Liver proposes that early identification and management of hepatic encephalopathy can improve outcomes 2

Monitoring and Follow-up

• The American Association for the Study of Liver Diseases recommends using telemedicine and remote monitoring technologies to help with early detection of complications and reduce hospital readmissions 4
• The European Association for the Study of the Liver suggests that continuous heart rate variability monitoring can identify patients at high risk of decompensation 4

Special Considerations

• The American Association for the Study of Liver Diseases defines acute-on-chronic liver failure (ACLF) as a condition characterized by acute onset with rapid deterioration, liver failure, and at least one extrahepatic organ failure 2
• The European Association for the Study of the Liver recommends considering early referral for liver transplantation evaluation in appropriate candidates 2
• The American Association for the Study of Liver Diseases proposes that a mean pulmonary arterial pressure ≥45 mmHg is an absolute contraindication to liver transplantation 5

Management of Severe Pancytopenia in Decompensated Cirrhosis

Evaluation and Treatment Approach

• Evaluate for signs of active bleeding, infection, or hepatic encephalopathy which may be precipitating or resulting from pancytopenia in patients with decompensated cirrhosis 6
• Assess for infections which may worsen pancytopenia and are common in decompensated cirrhosis 6
• Use restrictive transfusion strategy with hemoglobin threshold of 7 g/dl and target range of 7-9 g/dl for pancytopenia primarily due to hypersplenism 6
• Consider iron supplementation for anemia in patients with pancytopenia primarily due to hypersplenism 6
• Initiate volume replacement promptly with crystalloids or colloids to restore hemodynamic stability in patients with active bleeding 6
• Administer antibiotic prophylaxis with ceftriaxone for up to seven days in patients with advanced cirrhosis and active bleeding 6
• Use lactulose or lactitol for hepatic encephalopathy in patients with decompensated cirrhosis 6
• Avoid nephrotoxic drugs, large volume paracentesis without albumin, beta-blockers during acute bleeding, and other hypotensive drugs in patients with decompensated cirrhosis 6
• Consider TIPS for patients with medically refractory portal hypertensive gastropathy and compensated cirrhosis to improve pancytopenia related to hypersplenism 6
• Note that mean pulmonary arterial pressure ≥45 mmHg is an absolute contraindication to liver transplantation 7
• Surveillance for infections which may worsen both pancytopenia and liver function is crucial in patients with decompensated cirrhosis 6
• Overuse of blood products may worsen portal hypertension in patients with decompensated cirrhosis 6
• Inappropriate use of nephrotoxic medications can precipitate hepatorenal syndrome in patients with decompensated cirrhosis 6